سعر جينيرا 21 قرص 2024

Gynera (Bayer) combined oral contraceptive: 21 coated tablets, each containing ethinylestradiol 0.03 mg and gestodene 0.075 mg (strength from the Israeli MoH Gynera leaflet).

• Prevention of pregnancy (oral contraception).Israel Ministry of Health - Israeli Drug Registry
• Oral contraception.electronic medicines compendium (emc), UK

• Common adverse reactions include nausea, abdominal pain, weight increase, headache, depressed or altered mood, and breast pain or tenderness.International label, equivalent formulation · electronic medicines compendium (emc), UK
• Serious adverse reactions include venous and arterial thromboembolic events (e.g. DVT, pulmonary embolism, myocardial infarction, stroke).International label, equivalent formulation · electronic medicines compendium (emc), UK

• Presence or risk of venous thromboembolism (current or past VTE such as DVT or pulmonary embolism, known hereditary or acquired predisposition, major surgery with prolonged immobilisation, or high risk due to multiple risk factors).International label, equivalent formulation · electronic medicines compendium (emc), UK
• Presence or risk of arterial thromboembolism (current or past arterial thromboembolism, myocardial infarction, angina, stroke or TIA; hereditary or acquired predisposition; history of migraine with focal neurological symptoms; high risk due to multiple risk factors or one serious risk factor such as diabetes with vascular symptoms, severe hypertension or severe dyslipoproteinaemia).International label, equivalent formulation · electronic medicines compendium (emc), UK
• Presence or history of severe hepatic disease until liver function values return to normal; presence or history of liver tumours (benign or malignant); known or suspected sex-steroid-influenced malignancies (e.g. of the genital organs or breast); hypersensitivity to the active substances or excipients.International label, equivalent formulation · electronic medicines compendium (emc), UK

• Combined hormonal contraceptives increase the risk of venous and arterial thromboembolism; the risk is highest in the first year of use or when restarting after a break of 4 weeks or more. Individual risk factors (smoking especially over age 35, obesity, family history, immobilisation, postpartum period) must be assessed before starting and regularly thereafter.International label, equivalent formulation · electronic medicines compendium (emc), UK
• Hormonal contraceptives do not protect against HIV infection or other sexually transmitted diseases.International label, equivalent formulation · electronic medicines compendium (emc), UK

• Enzyme inducers (e.g. phenytoin, barbiturates, primidone, carbamazepine, rifampicin, St John's wort)Hepatic enzyme inducers can increase clearance of sex hormones and cause breakthrough bleeding and contraceptive failure; use a barrier method in addition during treatment and for 28 days after stopping the inducer.electronic medicines compendium (emc), UK
• Strong and moderate CYP3A4 inhibitors (e.g. azole antifungals, verapamil, macrolides, diltiazem, grapefruit juice)May increase plasma concentrations of the oestrogen, the progestogen or both.electronic medicines compendium (emc), UK
• EtoricoxibEtoricoxib 60-120 mg/day increased ethinylestradiol plasma concentrations 1.4- to 1.6-fold.electronic medicines compendium (emc), UK

• Not indicated during pregnancy; if pregnancy occurs during use, the tablets should be stopped. Extensive epidemiological studies have shown no increased risk of birth defects with inadvertent use in early pregnancy.International label, equivalent formulation · electronic medicines compendium (emc), UK
• Lactation may be influenced: combined oral contraceptives may reduce the quantity and change the composition of breast milk, and small amounts of steroids pass into milk; use is generally not recommended until the breast-feeding mother has completely weaned her child.International label, equivalent formulation · electronic medicines compendium (emc), UK

English text not available for this section.